FAQ

Azilect

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2017
02420052017

Related topics

Related topics

2 relations

Broader (2)

rasagilinerasagiline mesylate

Related mentions per year

Related mentions per year

1974-2018
197019801990200020102020
Azilect
rasagiline
rasagiline mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Multi Target Neuroprotective and Neurorestorative Anti-Parkinson and Anti-Alzheimer Drugs Ladostigil and M30 Derived from Rasagiline
Present anti-PD and -AD drugs have limited symptomatic activity and devoid of neuroprotective and neurorestorative property that… (More)
  • figure 1
Is this relevant?
2010
2010
Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30.
Based on a multimodal drug design paradigm, we have synthesized a multifunctional non-toxic, brain permeable iron chelator, M30… (More)
Is this relevant?
2010
2010
TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements.
Our recent studies demonstrated that propargylamine derivatives such as rasagiline (Azilect, Food and Drug Administration… (More)
  • figure 2
  • figure 3
  • figure 5
  • figure 4
  • figure 7
Is this relevant?
2010
2010
The delayed-start study in Parkinson disease: can't satisfy everyone.
Rasagiline has been studied as a Parkinson disease (PD) neuroprotective agent in 2 major clinical trials, utilizing the delayed… (More)
Is this relevant?
2010
2010
The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage.
Increasing evidence suggests that oxidative stress (OS)-induced pancreatic beta-cell impairments is involved in diabetes and… (More)
Is this relevant?
2009
2009
Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.
Novel therapeutic approaches for the treatment of neurodegenerative disorders comprise drug candidates designed specifically to… (More)
Is this relevant?
2008
2008
TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity.
We recently reported that propargylamine derivatives such as rasagiline (Azilect) and its S-isomer TVP1022 are neuroprotective… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2007
2007
Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.
The anti-Parkinson monoamine oxidase (MAO)-B inhibitor rasagiline (Azilect) was shown to possess neuroprotective activities… (More)
Is this relevant?
2007
2007
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro.
The anti-Parkinson, selective irreversible monoamine oxidase B inhibitor drug, rasagiline (Azilect), recently approved by the US… (More)
Is this relevant?
Review
2006
Review
2006
Rasagiline (Azilect) for Parkinson's disease.
  • The Medical letter on drugs and therapeutics
  • 2006
This Medicine Update is for people with Parkinson's disease who are taking, or thinking about taking, rasagiline. Independent… (More)
Is this relevant?